BlissBio Receives IND Approval from FDA for Novel ADC BB-1712

October 16, 2024 US Time --- BlissBio announced that its investigational new drug (IND) application of an innovative antibody-drug conjugate (ADC) BB-1712 was approved by the U.S. Food and Drug Administration (FDA). BB-1712, a B7-H3 targeted ADC with Eribulin as its toxin, is developed for the treatment of multiple solid tumors.

"As another ADC with global rights that we have developed," said Dr. Ziping Wei, co-founder, Chairman, and Chief Executive Officer of BlissBio, "the preclinical study results of BB-1712 have shown outstanding efficacy and safety, paving the way for its Phase 1 clinical trials. We are delighted to have reached this milestone and are very much looking forward to it showing excellent results in the upcoming clinical studies."

About BlissBio

Bliss Biopharmaceutical Co., Ltd. (“BlissBio”), founded in Hangzhou in December 2017, has grown into a clinical-stage biotech company dedicated to discovery, development and commercialization of oncology biological therapeutics. BlissBio currently has several innovative tumor-targeting ADCs undergoing Phase I and Phase II clinical trials, all of which have broad market prospects for a variety of cancer indications. The core team of BlissBio has a successful track record in the research and development and industrialization of multiple products in this field, a variety of technology platforms, a rich pipeline at different stages, and the capability to manufacture antibodies and ADCs that meet international GMP standards in its own facilities. With “Together, We Improve Human Health” as the core value, through international and domestic collaborations, BlissBio works closely with domestic and international peers to jointly promote the research, development and industrialization of differentiated innovative biologics therapeutics with global competitiveness.